Adjuvant nivolumab (NIVO) vs ipilimumab (IPI) in resected stage III/IV melanoma: 4-y recurrence-free and overall survival (OS) results from CheckMate 238
No Thumbnail Available
Identifiers
Date
2020-09-01
Authors
Weber, J.
Del Vecchio, M.
Mandala, M.
Gogas, H.
Arance Fernandez, A. M.
Dalle, S.
Cowey, C. L.
Schenker, M.
Grob, J-J.
Sileni, V. Chiarion
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
Metrics
Export
